Researcher: More Premarket CER Would Allow FDA To Focus On Big Therapeutic Advances
Mandating comparative effectiveness studies in premarket drug reviews could reduce the number of new pharmaceutical applications for products that are exhausting limited FDA review resources without providing substantive improvement over what has already been marketed, according to a prominent researcher with a history of provoking the drug industry on both safety and efficacy issues.
You've followed a link to an article or document on InsideHealthPolicy.com.
There are three ways you can access this content.
Subscriber Login
If you are an InsideHealthPolicy.com subscriber, or you have an active trial subscription, please login here:
Take A Trial Subscription
If you haven't already had a trial subscription to InsideHealthPolicy.com, you can sign up for one right now. Just click on the link below to get started -- you'll get full access for one month, including access to our newsletters, Inside CMS and FDA Week, plus daily news updates by e-mail and much, much more.
Buy This Article
You can also buy this and other individual InsideHealthPolicy.com articles by going to the InsideHealthPolicy.com NewsStand. Articles are $5 apiece. We'll even give you your first download free.
Here's a direct link to this article on the NewsStand.